Rachel Williams

Bluebird bio has received word from the FDA that its gene therapy candidate, lovotibeglogene autotemcel (lovo-cel) for sickle cell disease (SCD), won’t undergo an advisory committee review. This development was made public by the company on Wednesday. The Biologics License Application (BLA) for Lovo-cel is currently in the regulatory assessment phase, with the FDA’s decision […]